Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

Biomarkers and correlative endpoints for immunotherapy trials.

Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e287.

PMID:
23714525
[PubMed - in process]
Free Article
2.

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ.

Cancer. 2011 Mar 15;117(6):1262-71. doi: 10.1002/cncr.25526. Epub 2010 Oct 19.

PMID:
20960500
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
[PubMed - indexed for MEDLINE]
4.

Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.

[No authors listed]

BioDrugs. 2003;17(1):69-72.

PMID:
12534322
[PubMed - indexed for MEDLINE]
5.

The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Ferrari AC, Quinn DI.

Clin Adv Hematol Oncol. 2011 Dec;9(12 Suppl 28):1-14; quiz 15-6. Review.

PMID:
22407145
[PubMed - indexed for MEDLINE]
6.

Cellular immunotherapy for refractory hematological malignancies.

Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ.

J Transl Med. 2013 Jun 19;11:150. doi: 10.1186/1479-5876-11-150.

PMID:
23782682
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Alternate endpoints for screening phase II studies.

Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ.

Clin Cancer Res. 2009 Mar 15;15(6):1873-82. doi: 10.1158/1078-0432.CCR-08-2034. Epub 2009 Mar 10. Review.

PMID:
19276273
[PubMed - indexed for MEDLINE]
Free Article
8.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
[PubMed - indexed for MEDLINE]
9.

Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.

Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, Lubet RA, Sigman CC.

J Cell Biochem Suppl. 1995;23:1-9. Review.

PMID:
8747372
[PubMed - indexed for MEDLINE]
10.

Improved endpoints for cancer immunotherapy trials.

Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J.

J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8. Review.

PMID:
20826737
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.

Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT.

Cancer Metastasis Rev. 2006 Jun;25(2):233-42. Review.

PMID:
16770535
[PubMed - indexed for MEDLINE]
12.

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.

Methy N, Bedenne L, Bonnetain F.

BMC Cancer. 2010 Jun 10;10:277. doi: 10.1186/1471-2407-10-277.

PMID:
20537166
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy.

Disis ML.

Cancer Immunol Immunother. 2011 Mar;60(3):433-42. doi: 10.1007/s00262-010-0960-8. Epub 2011 Jan 8. Review.

PMID:
21221967
[PubMed - indexed for MEDLINE]
14.

Immunotherapy for prostate cancer: biology and therapeutic approaches.

Cha E, Fong L.

J Clin Oncol. 2011 Sep 20;29(27):3677-85. doi: 10.1200/JCO.2010.34.5025. Epub 2011 Aug 8. Review.

PMID:
21825260
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group.

Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.

PMID:
23680111
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities.

Dunn BK, Jegalian K, Greenwald P.

Recent Results Cancer Res. 2011;188:21-47. doi: 10.1007/978-3-642-10858-7_3. Review.

PMID:
21253787
[PubMed - indexed for MEDLINE]
17.

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG.

Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14. Review.

PMID:
19684076
[PubMed - indexed for MEDLINE]
Free Article
19.
20.

Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.

Lieberman R.

Urology. 2001 Apr;57(4 Suppl 1):224-9.

PMID:
11295633
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk